ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on July 26, 2024, covering events occurring on July 24, 2024. The filing reports the promotion of Brad Tade to the positions of Chief Financial Officer and Treasurer, effective July 24, 2024.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change is the appointment of Brad Tade as Chief Financial Officer and Treasurer. Mr. Tade previously served as Vice President, Financial Operations since joining the company in June 2023.
Guidance, Outlook, and Compensation Details
The filing details a new Employment Agreement for Mr. Tade with the following terms:
- Base Salary: $435,000 annually.
- Target Bonus: 45% of base salary, contingent on performance milestones.
- Equity Grants:
- Option to purchase 115,100 shares of common stock, vesting over four years (25% at one-year anniversary, remainder monthly).
- 72,400 restricted stock units (RSUs), vesting in four equal annual installments.
- Severance Provisions:
- Termination without Cause or for Good Reason: 12 months of base salary paid in monthly installments.
- Termination without Cause/Good Reason within one year of a Change of Control: 15 months of base salary plus 1.5x Target Bonus paid in a lump sum.
- Acceleration of all stock options and RSUs upon qualifying termination events.
The agreement includes standard non-competition, non-solicitation, and confidentiality covenants. No financial guidance or operational outlook was provided in this filing.
Investor Verification Checklist
- Verify the full text of the Employment Agreement filed as Exhibit 10.1 for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the impact of the new equity grants on total shareholder dilution.
- Review the company's recent financial statements (10-K or 10-Q) for current liquidity and cash burn rates, as this 8-K does not contain financial data.
- Monitor future filings for any changes to the Board of Directors or additional executive appointments.